ArticleMolecular medicine reports2019
BNIPL‑2 expression is correlated with the prognosis and regulates the proliferation of colorectal cancer through CD44.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- BNIPL is a promising biomarker of laryngeal cancer: novel insights from bioinformatics analysis and experimental validation.BMC medical genomics · 2024Article
- Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.Theranostics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) currently leads to many deaths worldwide. The regulatory mechanism, however, remains largely unclear. In the present study, bioinformatics methods were used to identify genes associated with CRC prognosis and to detect the molecular signals regulating the cell cycle in two CRC cell lines. It was revealed that BNIPL‑2 expression was higher in CRC tissues than in adjacent tissue samples. Upregulation of BNIPL‑2 was correlated with poor prognosis and the adverse malignant stages T and M. BNIPL‑2 was also associated with signaling pathways involved in cancer cell growth. BNIPL‑2 overexpression promoted cell proliferation and increased the proportion of cells in the G2/M phase. Knockdown of BNIPL‑2 inhibited cell proliferation. CD44 was regulated by BNIPL‑2 and promoted cell proliferation. Downregulation of CD44 suppressed cell proliferation and rescued the cell proliferation promoted by BNIPL‑2. Overexpression of CD44 restored the cell proliferation suppressed by BNIPL‑2 knockdown. The present study not only suggested that BNIPL‑2 may be a potential biomarker of CRC but also indicated that BNIPL‑2 regulates CRC cancer proliferation via CD44, which could be a diagnostic and clinical treatment target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.